ENZARAD (ANZUP 1303): Phase III Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.
Scott Williams, Christopher J Sweeney, Hayley Thomas, Blossom Mak, Alison Zhang, Tee Sin Lim, Chakiath Jose, Jarad Martin, Nitya Patanjali, David Pryor, Phuong Tran, Stephen Mangar, Alina M Mihai, Carys Thomas, Simon Gampenrieder, Sonia Yip, Leanna Cheung, Sandra Lee, Annabelle Goodwin, Annette Haworth, Anna Walsh, Paul J Kelly, Simon Hughes, Andrew Martin, Ray McDermott, Martin Stockler, Ian D Davis, Paul L Nguyen
J Clin Oncol JCO2601794
摘要
摘要
PURPOSE: The effects of adding enzalutamide to androgen deprivation therapy (ADT) and radiotherapy for high-risk localized or locally advanced prostate cancer were unknown. METHODS: This is an open-label, phase III trial of definitive prostate radiotherapy with 24 months of ADT and 1:1 random assignment to either enzalutamide (160 mg once daily for 24 months) or an older nonsteroidal antiandrogen (NSAA) for 6 months. The primary end point was metastasis-free survival on conventional imaging (MFS-CI) with computed tomography and/or 99mTc-bone scintigraphy. Radiation to pelvic lymph nodes was required for cN1 disease but optional for cN0. RESULTS: A total of 802 participants were randomly assigned. After a median follow-up of 92 months, 207 MFS-CI events were reported (98 enzalutamide, 109 NSAA) with 8-year MFS-CI rates of 74% versus 72% (hazard ratio [HR], 0.88 [95% CI, 0.67 to 1.15]; P = .34). Prespecified subgroup analyses noted that enzalutamide was associated with a possible MFS-CI benefit in the subgroup undergoing planned pelvic nodal radiotherapy, n = 324 (HR, 0.47 [95% CI, 0.29 to 0.76]; Padjusted = .004). Grade 3 to 5 adverse events were reported in 185 participants in each arm. CONCLUSION: The use of enzalutamide rather than NSAA in addition to radiotherapy and ADT for 2 years showed no significant MFS-CI or overall survival improvement at 8 years.
KM 提取结果
0 个 Figure · 0 个 KM 面板